GRI Bio, Inc. (GRI) stock
GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.27−0.08 (-5.95%)
Close on Nov 18, 2026Market cap $2.78MP/E –Yield –
GRI Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
GRI Bio's operating income for the twelve months ending Jun 30, 2026 was -$9.68M. For fiscal 2025 it was -$11.98M. The highest annual figure on record is -$2.24M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.98M | – |
| FY2024 | Dec 31, 2024 | -$8.24M | – |
| FY2023 | Dec 31, 2023 | -$11.39M | – |
| FY2022 | Dec 31, 2022 | -$2.24M | – |
| FY2021 | Dec 31, 2021 | -$9.26M | – |
| FY2020 | Dec 31, 2020 | -$4.79M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.65M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.90M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.05M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.95M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.90M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.03M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.44M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.93M | – |
| Q1 FY2023 | Mar 31, 2023 | -$988.00K | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$186.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$189.00K | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.63M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.25M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.31M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.60M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.46M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.03M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.14M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.16M | – |
See a number that looks wrong?